Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ocumension Therapeutics ( (HK:1477) ) just unveiled an announcement.
Ocumension Therapeutics has completed enrollment of 195 patients in a real-world study of OT-703 (ILUVIEN), a fluocinolone acetonide intravitreal implant for diabetic macular edema, at the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China. The implant, already approved by the U.S. FDA and registered in Hong Kong, is the only corticosteroid intraocular implant with a three-year sustained-release profile for DME, and the Hainan study marks a key step in generating local real-world evidence to support its regional rollout and potential commercialization across Greater China and other Asian markets, although the company cautions that successful commercialization is not assured.
The most recent analyst rating on (HK:1477) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics is an ophthalmic-focused biopharmaceutical company specializing in the development and commercialization of treatments for eye diseases in Greater China and selected Asian markets. Through licensing agreements, such as its exclusive deal with Alimera Sciences for ILUVIEN, the company is building a portfolio targeting conditions like diabetic macular edema, with a strategic focus on bringing advanced international ophthalmic therapies into the region.
Average Trading Volume: 1,075,277
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.1B
See more data about 1477 stock on TipRanks’ Stock Analysis page.